Your email has been successfully added to our mailing list.

×
0.0429530201342282 0.0429530201342282 0.0429530201342282 0.0429530201342282 0.0429530201342282 0.0738255033557047 0.0738255033557047 0.0791946308724833
Stock impact report

Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies

Compugen Ltd. - Ordinary Shares (CGEN) 
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: cgen.com/investors/overview
Company Research Source: PR Newswire
HOLON, Israel, April 6, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM902, an immuno-oncology therapeutic antibody targeting TIGIT, in patients with advanced malignancies. This Phase 1 open-label clinical trial is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of escalating doses of COM902 monotherapy in patients with advanced malignancies who have exhausted all available standard therapies. The study will be conducted in multiple leading oncology clinical centers in the United States. Manish Sharma, M.D., Associate Director of Clinical Research at START Midwest (Grand Rapids, MI) and a Principal Investigator in the Phase 1 COM902 study, said, "Being part of Compugen's ongoing COM701 Phase 1 study, we are excited to expand our relatio Show less Read more
Impact Snapshot
Event Time:
CGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CGEN alerts
Opt-in for
CGEN alerts

from News Quantified
Opt-in for
CGEN alerts

from News Quantified